New drug may make stem cell transplants safer for older patients
NCT ID NCT05823571
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) after a mini stem cell transplant in people aged 60 and older with certain blood cancers. The study also aims to see if itacitinib allows doctors to use shorter courses of other immune-suppressing drugs. About 32 participants will receive itacitinib alongside standard transplant care to find the safest and most effective regimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- itacitinib
- What this could lead to
- If it works, this could lead to safer stem cell transplants with fewer complications and less need for long-term immune-suppressing drugs.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants, so it is primarily testing safety. It may not show clear benefits, and there are risks from the transplant and immune suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Frailty check may steer safer cancer care for seniors
- Talking about the end: could guided conversations reduce futile cancer treatments?